ARIAD to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that Paris Panayiotopoulos, president and chief executive officer, will provide an overview of the Company’s business at two upcoming investor conferences:

• The Cowen and Company 36th Annual Health Care Conference being held in Boston on Wednesday, March 9, at 8:40 a.m. (ET)
• The Barclays Global Healthcare Conference being held in Miami on Thursday, March 17, at 8:00 a.m. (ET).

The ARIAD presentations will be webcast live and can be accessed by visiting the investor relations section of the Company's website at http://www.ariad.com/investor. Replays of these presentations will also be available and archived on the site for three weeks.

About ARIAD

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).

View source version on businesswire.com: http://www.businesswire.com/news/home/20160229005279/en/

ARIAD Pharmaceuticals, Inc.
For Investors
Maria Cantor, 617-621-2208
[email protected]
or
For Media
Liza Heapes, 617-621-2315
[email protected]

Source: ARIAD Pharmaceuticals, Inc.

You May Also Be Interested In

• Exchange Traded Concepts and ARIAM Global launch ARIA an Actively Managed ETF Led by a Portfolio Manager with a Ph.D. in AI and Computer Science
• Best Crypto to Buy in August 2026: BTC and XRP Grind While Pepeto Wallets Race for Listing
• Dallas County Schools Show Continued Progress in 2026 Accountability Ratings